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Abstract
Background: The aim of this study was to assess the treatment results and toxicity profiles of helical tomotherapy
(HT) for postoperative high-risk oral cavity cancer.
Methods: From December 6, 2006 through October 9, 2009, 19 postoperative high-risk oral cavity cancer patients
were enrolled. All of the patients received HT with (84%) or without (16%) chemotherapy.
Results: The median follow-up time was 17 months. The 2-year overall survival, disease-free survival, locoregional
control, and distant metastasis-free rates were 94%, 84%, 92%, and 94%, respectively. The package of overall
treatment time > 13 wk, the interval between surgery and radiation ≤ 6 wk, and the overall treatment time of
radiation ≤ 7 wk was 21%, 84%, and 79%, respectively. The percentage of grade 3 mucositis, dermatitis, and
leucopenia was 42%, 5% and 5%, respectively.
Conclusions: HT achieved encouraging clinical outcomes for postoperative high-risk oral cavity cancer patients
with high compliance. A long-term follow-up study is needed to confirm these preliminary findings.
Background
The location of the primary tumor site in head and neck
cancer is an important prognostic factor [1-3]. Amdur
et al. [1] reported that the primary site of head and neck
tumors is significantly important for predicting disease
control. In addition, Peters et al. [2] also reported that
oral cavity primary tumors are one of the risk factors
associated with progressively increased risk of recurrence.
In another published report, the authors also found that
oropharyngeal cancer patients had the greatest locoregio-
nal recurrence-free survival rate among oral cavity cancer
(OCC) patients [3]. These reports suggest that the treat-
ment for OCC is a challenge.
Besides prognostic factors [4,5] directly related to the
tumor or the surgical specimen, treatment-related
variables may also account for differences in clinical
outcomes, including the total dose of radiation [2],
package of overall treatment time (POTT) [6] and the
overall treatment time of radiation therapy (OTTRT)
[7]. In a prospective randomized study, a significantly
higher locoregional recurrence rate was found among
patients who received a dose of < 54 Gy compared with
those who received a dose of > 57.6 Gy [2]. An interval
between surgery and radiotherapy prolonged than 7 wks
was associated with a significant reduction in locoregio-
nal control [6]. In addition, shorter OTTRT was asso-
ciated with better overall survival rate [7].
Helical tomotherapy (HT) is an image-guided new
CT-based rotational intensity modulated radiotherapy
(IMRT) that delivers highly conformal dose distributions
to the target tissue [8]. Thus, this complex rotational
treatment method has the ability to spare critical organs
exposure to unnecessary radiation. The preliminary stu-
dies of HT for locally advanced oropharyngeal cancer
achieved encouraging results [9].
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yngeal tumors treated with HT. In addition, HT reduced
the incidence of side effects during treatment that could
made treatment without interruption possible. Because
OCC is associated with progressively increased risk of
recurrence, the clinicians are concerned about how
radiation dosage, POTT, and OTTRT affect treatment
results. Therefore, we report our initial clinical experi-
ence with postoperative OCC patients treated with HT,
focusing on the clinical outcome and toxicity.
Methods
Patient characteristics
From December 6, 2006 through October 9, 2009, we
identified 19 patients with locally advanced OCC who
had undergone surgery followed by postoperative HT
(POHT) with or without chemotherapy at Far Eastern
Memorial Hospital. Retrospective patient data was col-
lected with the approval of the Institutional Review
Board of Far Eastern Memorial Hospital. Staging investi-
gations included complete history and physical examina-
tion, fiber optic endoscopic evaluation, complete blood
counts, liver function tests, chest X-ray, magnetic reso-
nance imaging (MRI) of the head and neck region,
which was done before surgery, and a dental evaluation.
Bone scans, computed tomography (CT) of the chest
and abdomen were obtained whenever possible before
the beginning of treatment. The disease was staged
according to the American Joint Committee on Cancer
Staging Classifications 6
th edition, which is based on the
pathological findings after radical surgery.
Radiation therapy
A type-S thermoplastic head frame (MT-CHFN-C,
Civco MedTec, Kalona, Iowa, USA) were used for head
and shoulder immobilization. CT with a 3-mm slice
thickness was done for treatment planning. Target
objects and normal structures were contoured using the
Pinnacle 3 Treatment Planning System (Philips Health-
care, Madison, Wisconsin, USA). The preoperative MRI
images were retrieved on a Pinnacle workstation and
fused with the CT images for contouring and preopera-
tively confirming the location of the gross tumor and
postoperative flap in all patients.
Delineation of target volumes
The determination of clinical target volumes (CTVs)
was based on the incidence and location of metastatic
neck nodes from various head and neck subsides [10].
The CTV1, using preoperative MRI fused with the CT
images to confirm the location of the gross tumor and
the postoperative flap, was defined as encompassing
the preoperative gross tumor and postoperative flap
plus a 0.8- to 1-cm margin, which included the
resection bed with soft-tissue invasion by the tumor or
extracapsular extension (ECE) by metastatic neck
nodes truncating air, and uninvolved bones. CTV2 was
defined as a high-risk subclinical area primarily includ-
ing the pathologically uninvolved cervical lymph
nodes, deemed as elective nodal regions, or prophylac-
tically treated neck areas [3,10,11]. CTV3 was desig-
nated as the low-risk area of potential subclinical
disease. To account for organ motion and patient
setup errors, the planning target volumes (PTVs)
encompassed the CTVs plus a margin 3 mm. CTV1
received 60-66 Gy in 30-33 fractions; 64-66 Gy was
delivered to high-risk OCC patients and 60 Gy was
delivered to intermediate-risk OCC patients. For
CTV2, 59.4-60 Gy/30-33 fractions was delivered and
for CTV3, 51.2-54 Gy/30-33 fractions was delivered.
T h ed o s ec o n s t r a i n t sf o ro r g a n sa tr i s k( O A R s )w e r e
as follows: (1) brainstem: maximum dose, 54 Gy; (2)
spinal cord: maximum dose, 45 Gy; (3) optic chiasm
and optic nerve: maximum dose, 45 Gy; (4) bilateral
parotid glands: mean dose, < 30 Gy, median dose, <
26 Gy, and whole parotid gland volume with < 20 Gy
that larger than 20 cc; (5) 2/3 of glottic larynx < 50
Gy; and (6) inner ear: mean dose, < 50 Gy; (7) mand-
ible: maximum dose: 70 Gy.
The field width, pitch, and modulation factor (MF)
used for treatment planning optimization were 2.5 cm,
0.32, and 3.0, respectively. Maximum importance was
given to target dose coverage. The constraints on dose
and penalty were adjusted accordingly during optimiza-
tion. All patients underwent daily megavoltage CT for
setup verification [12].
Dose-volume analysis of treatment plans
Dose-volume histograms of the PTVs and the critical
normal structures were analyzed. No more than 20% of
the PTV received more than 110% of its prescribed
doses, and no more than 1% of any PTV received less
than 93% of its prescribed doses. For the critical organs
with functional subunits organized in a series such as
the brainstem, spinal cord, and cochlea, the maximum
point dose was examined. For critical organs with func-
tional subunits organized in parallel such as the parotids
(i.e., entire gland including deep and superficial lobes),
the median dose was examined.
Chemotherapy
Sixteen patients received concurrent chemotherapy.
Three patients did not receive chemotherapy concur-
rently with radiotherapy because they refused concur-
rent therapies. During radiotherapy, the patients who
received chemotherapy were treated with cisplatin (30
mg/m
2) plus fluorouracil (5-FU, 425 mg/m
2)a n dl e u -
covorin (30 mg/m
2), both intravenously each week.
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All patients were evaluated at least once a week during
radiotherapy. At the completion of radiation, patients were
then evaluated every 3 months for the first 2 years. At
each follow-up visit, a physical examination, including a
fiber-optic endoscopic examination and palpation of the
neck was performed. Post-treatment MRI of the oral cavity
and neck was done 1, 3, and 6 months after completion of
radiotherapy. Acute toxicities (occurring < 90 days after
beginning radiotherapy) and late toxicities (occurring > 90
days after beginning radiotherapy) were defined and
graded according to the Common Terminology Criteria
for Adverse Events v3.0 (CTCAE v3.0). The earliest date
of detecting Grade 3 or worse toxicity was recorded.
Statistical methods
Descriptive statistics (mean, median, proportions) were
calculated to characterize the patient, disease, and treat-
ment features as well as toxicities after treatment. The
overall survival (OS), disease-free survival (DFS), locore-
gional progression-free (LRPF), and distant metastases-
free (DMF) rates were estimated using the Kaplan-
Meier product-limit method [13]. Freedom from local
progression was defined as the absence of the primary
tumor on physical examination and on any radiographic
examination (CT and MRI). Durations were calculated
f r o mt h ed a t eo fp a t h o l o g i cp r o o f .A l la n a l y s e sw e r e
performed using the SPSS, version 12.0 (SPSS, Chicago,
Illinois, USA).
Results
Patient characteristics
Seventeen men and 2 women were included in the
study. They had a median age of 50 years (range, 24-70
years). The subsites of the tumors were located in the
oral tongue (47%) and buccal mucosa (32%). Of the 19
patients, 53% had positive or close surgical margins,
while 42% were ECE (+). The disease stage distribution
included Stage II (1/19, 5%), Stage III and IVa (18/19,
95%). Almost all (90%) of the patients had more than
two risk factors. (Table 1)
Treatment outcomes
The median and mean follow-up time was 17 months
and 31 ± 2 months (range, 4-34 months). The 2-year
actuarial OS, DFS, LRPF, and DMF rates were 94%,
84%, 92%, and 94%, respectively. (Figure 1 and Table 2)
One patient had disease progression with lung metasta-
sis and another had involve-field failure after CCRT 6
and 13 months, respectively.
Compliance with and delivery of treatment
All patients received rotational, multiple-angle beam
HT. More than 80% (16/19) of the patients received
Table 1 Patient characteristics
Tomotherapy (N = 19)
Variable No. of patient (%)
Age (years)
Median 50
Range 24-70
Gender
Male 17 (89.5%)
Female 2 (10.5%)
Smoking
Yes 16 (84.2%)
No 3 (15.8%)
Alcohol drinking
Yes 10 (52.6%)
No 9 (47.4%)
Betel nut chewing
Yes 12 (61.2%)
No 7 (36.8%)
^ECOG Performance Status
0 9 (47.4%)
1 9 (47.4%)
2 1 (5.2%)
Subsite
Oral tongue 9 (47.4%)
Buccal mucosa 6 (31.6%)
Gingiva 3 (15.8%)
Retromolar trigone 1 (5.3%)
Pathology
Squamous cell carcinoma 19 (100%)
Resection-margin status
Positive 1 (5.3%)
Close 9 (47.4%)
Negative 9 (47.4%)
Extracapsular spread
Positive 8 (42.1%)
Negative 11 (57.9%)
Perineural involement
Positive 14 (73.7%)
Negative 5 (26.3%)
Lymphovascular Space Involvement
Positive 13 (68.4%)
Negative 6 (31.6%)
Lymph-node involvement ≥2 Positive
Positive 11 (57.9%)
Negative 8 (42.1%)
Pathology stage:
Tumor stage
Stage II 1 (5.3%)
Stage III 5 (26.3%)
Stage IVA 13 (68.4%)
Stage IVB 0
Primary Tumor stage
T1 0
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T h em e d i a nd o s eo fr a d i a t i o nw a s6 6G y( r a n g e :6 0 - 6 6
Gy). The POTT (means from surgery to CCRT or
POHT last day) > 13 weeks was only 21%. The interval
between operation and CCRT or postoperative radio-
therapy (IBOR) ≤ 6w kvs. > 6 wk was 84% vs. 16%. The
overall treatment time of radiotherapy (OTTRT) ≤ 7w k
vs. > 8 wk was 79% vs. 21%. (Table 3)
Dose-volume analysis
The average of D93% and V110% for the PTVs was 65.0
± 2.7 Gy and 0.14 ± 0.34%, respectively. The mean of
the median doses for both sides of the parotid glands
was 25.7 Gy (right side: 19.4-39.0 Gy; left side: 11.5-51.6
Gy). The averages of the mean doses for the right and
left side parotid glands were 29.6 Gy and 30.1 Gy,
respectively. The means of the maximal doses for the
spinal cord and brain stem were 34.7 ± 5.7 Gy (range:
23.3-44.5 Gy) and 28.2 ± 6.4 Gy (range: 8.9-36.1 Gy),
respectively. The mean dose for the larynx was 30.6 ±
6.2 Gy (range: 24.3-43.9 Gy).
Toxicities
The acute toxicities of POHT with or without che-
motherapy are detailed in Table 4. No grade 3 of acute
toxicity for xerostomia, anemia, thrombocytopenia, or
body weight loss was noted during CCRT or POHT. Of
the 19 patients, (5%, 1/19) had grade 3 dermatitis, 5%
(1/19) leucopenia, and 42% (8/19) had grade 3 mucositis
during treatment. For acute toxicity, 9 of 19 patients
had grade 2 xerostomia, while the others had grade 1
xerostomia. On follow up, all patients recovered to
grade 1 xerostomia.
Discussion
The previous reports of locally advanced head and neck
cancer patients who underwent surgery followed by RT
concurrent with or without chemotherapy had 2-year
estimated OS, DFS, and LRPFS of 63%-83%, 58%-87%,
and 65%-91%, respectively [3-5,14-19]. The 2-year
actuarial OS, DFS, LRPFS, and DMF rates in the current
study are 94%, 84%, 92%, and 94%, respectively. These
results are compatible with the previous reports, sug-
gesting HT is a feasible treatment for high-risk post-
operative OCC patients. (Table 2)
The patients with ECE (+), close or positive surgical
margins, and two or more other adverse features were
categorized as the high-risk group. All patients in the
current study are in the high-risk group. (Table 1) A
Dutch group compared the intermediate-risk group and
the high-risk group and found that the 3-year LRCs for
OCC were 87% and 66%, respectively (p = 0.0005) [7].
In a report from the University of Florida, the 5-year
LRC rate was 63% for those in the unfavorable group
[20]. University of Texas M. D. Anderson Cancer Center
also noted the 5-year actuarial LRC was 42% for the
high-risk group [6]. The previous reports point out the
LRC rate for the high-risk group of head and neck can-
cer ranges from 42%-66% [6,7,20]. POHT resulted in a
L R Cr a t eo f9 2 %i nt h ec u r r e n ts t u d y .T h er e s u l t ss u p -
port the feasibility of HT for postoperative OCC
treatment.
IMRT offers excellent outcomes for LRC and OS in
postoperative head and neck cancers [3,15-19]. (Table 2)
Nevertheless, the LRC for OCC is lower than for other
subsites of head and neck cancer, even when treated
with IMRT [3]. Hinermen et al. [20] indicated that the
LRC of T3/T4 and stage III/IV was worse than early T
and early stages, respectively. Although Studer et al.
[15] showed excellent outcomes for postoperative OCC
Figure 1 Actuarial 2-year disease-free survival rates for
postoperative oral cavity cancer patients treated with
postoperative helical tomotherapy, with or without concurrent
chemotherapy.
Table 1 Patient characteristics (Continued)
T2 6 (31.6%)
T3 8 (42.1%)
T4a 5 (26.3%)
T4b 0
Regional Lymph Node stage
N0 5 (26.3%)
N1 3 (15.8%)
N2a 0
N2b 8 (42.1%)
N2c 3 (15.8%)
N3 0
Abbreviations:
ECOG Performance Status = Eastern Cooperative Oncology Group
Performance Status.
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III/IV in their study vs.o u r si s3 2 %vs.68% and 68%
vs.95%, respectively. Because ECE (+) data and positive
operating margins were not shown in the Studer study,
we compared the proportions of T3/T4 and stage III/IV
to explain the potential benefits of local control by HT
for postoperative OCC. Gomez et al. [19] also provided
impressive results for postoperative OCC treated with
IMRT. The rates of LRC, T4, ECE (+) and positive oper-
ating margins in their study were 84%, 31%, 36%, and
43%, respectively. In the current study, the correspond-
ing rates were 92%, 26%, 42%, and 53%, respectively. HT
provided potential benefits for local control of post-
operative OCC patients with high risk factors. Nonethe-
less, the probable reasons for these benefits could be
either too short follow-up or the addition of chemother-
apy to the radiotherapy regimen. Additionally, the
image-guidance function of HT provided high quality
and adaptive treatments such as planned rescanning and
recontouring of the tumor target.
The other factors contributing to LRC and OS are
dose, POTT, IBOR, and OTTRT. In a randomized study
at M. D. Anderson Cancer Center, a significantly higher
locoregional recurrence rate was found among patients
who received doses of < 54 Gy; those who had signifi-
cantly higher locoregional control rates received doses ≥
63 Gy [2]. Patients with advanced head and neck cancer
who were at high or intermediate risk of developing
locoregional recurrences from various sites who received
63 Gy over the course of 7 wk vs.6 3G yo v e r5w k
achieved locoregional control with the accelerated radio-
therapy approximately 15% greater than those treated
with conventional radiotherapy techniques. Moreover,
OTTRT > 8 wk was the most important prognostic fac-
tor both in the high-risk and intermediate-risk patient
groups [7]. These studies indicated a 6%-7.8% improve-
ment of locoregional control with every week of short-
ening of the overall treatment time. For patients treated
by conventional radiation techniques, Langendijk et al.
[ 7 ]r e p o r t e dt h a tt h eO T T R Tw a s≤ 8 wk in 52% of
patients and the OTTRT was > 8 wk in 16% o patients.
Muriel et al. [21] also reported similar results for post-
operative irradiation times ≤ 55 days (39% of patients)
and > 56 days (61% of patients). In contrast, 95% of our
patients had OTTRT ≤ 8w k ,w h i l eo n l y5 %h a d
OTTRT > 8 wk in our study. Our data suggests that
Table 2 The 2-year estimated overall survival (OS), disease-free survival (DFS), locoregional progress-free survival
(LRPF) and distant metastasis-free (DMF) rate of postoperative irradiation with or without of chemotherapy for high-
risk oral cavity cancer at the Far Eastern Memorial Hospital (FEMH) compared with selected published series
Selected
published
Series
No. of
postoperative
patient
Proportion
of OCC
T3
-4
LN
involvement
≥2 Positive
Stage
III, IV
Resection
margin positive
or close
ECE PNI LVSI/
or
VEs
Mod-
Ality
2-year
(%) (%) (%) (%) (%) (%) (%) (%) (%) OS
(%)
DFS
(%)
LR
PF
(%)
DMF
(%)
Eisbruch et
al.[3]
133 20 - - 91 7 48 - - OP®
IMRT
+C/T
- - 65¶ -
Studer et al.
[15]
28 100 32 57 68 - - - - OP®
IMRT
+/-C/T
83 87 91 95
Chao KS et
al.[16]
65 17.6 52 56 86 - - - - OP®
IMRT
- - 90 -
Yao M et al.
[18]
55 100 56 36 91 OP®
IMRT
68 74 82 89
Gomez DR
et al.[19]
35 100 40 38 80 43 36 54 26 OP®
IMRT
+/-C/T
74 70 84 85
Chen WC et
al., Taiwan
[17]
22 100 - 32 100 5 32 - - OP®
IMRT
+/-C/T
72 64 - -
FEMH,
Taiwan
19 100 68 58 95 52.6 42.1 73.7 68.4 OP®
HT
+/-C/T
94 84 92 94
*Value estimated from survival curves. †High-risk OCC: extracapsular spread, Resection-margin positive or close, or more than one adverse factor. ¶ The estimated
2-year LRPF rate belong to OCC only.
Abbreviations:
OCC = oral cavity cancer; LN = Lymph node; ECE = Extracapsular extension; PNI = Perineural involvement; LVSI = Lymphovascular space involvement; VEs =
vascular embolisms; OS = overall survival; DFS = disease-free survival; LRPF= locoregional progress-free survival; DMF = distant metastasis-free; OP = operation;
RT = External beam radiation therapy; IMRT = intensity-modulated radiation therapy; HT = helical tomotherapy; C/T = chemotherapy; FEMH = Far Eastern
Memorial Hospital.
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parison with other modalities. The IBOR is recognized
as an important end point in some studies [6,20,22].
The results of the studies summarized in Table 3 indi-
cate the importance of POTT, IBOR, and OTTRT. In
the current study, most of the patients who received
POHT completed the treatment course during the
recommended intervals (POTT > 13 wk, IBOR ≤ 6w k ,
and OTTRT ≤ 7 wk: 21%, 84% and 79% of patients,
respectively) with a median high dose of 66 Gy. Thus,
Table 3 The package of overall treatment time (POTT), interval between operation and post-operation radiotherapy
(IBOR) and overall treatment time of radiation therapy (OTTRT) at the Far Eastern Memorial Hospital (FEMH)
compared with selected published series
Selected published studies Factors Percentage Locoregional
control
Disease-free
survival
Overall survival
(%) 2-
year
3-
year
5-
year
2-
year
3-
year
5-
year
2-
year
3-
year
5-
year
University of Texas M. D. Anderson Cancer
Center, USA [6]
POTT <11 wks 64.2% 81% 78% 76% 64% 58% 48%
>13 wks 10% 38% 38% 38% 25% 25% 25%
IBOR ≤6 wks 54.7% 78% 78% 75% 68% 58% 48%
>6 wks 45.3% 58% 50% 48% 50% 32% 25%
VU University Medical Center, Netherlands [7] POTT <11 wks 12% 86%
>13 wks 45% 71%
OTTRT ≤7 wks 31% 90-
82%
85-
75%
78-
58%
72-
49%
82-
65%
74-
55%
>8 wks 16% 56% 51% 42% 38% 53% 50%
University of Florida, USA [20] POTT ≤101
days
63% 70% 70% 70%
>101
days
17% 50% 40% 30%
IBOR ≤51
days
57% 72% 72% 72%
>51
days
17% 56% 50% 40%
University of Florida College of Medicine, USA
[22]
POTT <100
days
60%
>100
days
14%
University of Texas M. D. Anderson Cancer
Center, USA [2]
IBOR ≤6 wks 77%
>6 wks 64%
University Hospital, Avda, Spain [21] POTT ≤150
days
77%
>150
days
63%
IBOR ≤ 50
days
83%
>50days 68%
OTTRT ≤ 60
days
75%
>60
days
68%
FEMH, Taiwan POTT ≤11 wks 42.1% 92% 84% 94%
>13 wks 21.1%
IBOR ≤6 wks 84.2%
>6 wks 15.8%
OTTRT ≤ 7 wks 78.9%
> 8 wks 5.2%
Abbreviation:
POTT = Package of overall treatment time; IBOR = Interval between operation and post-operation radiotherapy; OTTRT = Overall treatment time of radiation.
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can result in high compliance rates that offer encoura-
ging results.
The rates of fistula are reported to range from 8% to
29% in patients treated with surgery and postoperative
radiotherapy (PORT) [23]. (Table 4) The fistula forma-
tion rate among our patients was 11%; this result
reflects the fact that HT did not increase the rate of fis-
tula formation even under the median high dose treat-
ment, with or without concurrent chemotherapy. Grade
3 dermatitis occurred with PORT concurrent with che-
motherapy at a rate of 3%-29% [4,14,19]; the corre-
sponding rate in the current study was 5%. (Table 4) In
the report by Gomez et al. ,as i m i l a rr a t ef o rg r a d e3
dermatitis was noted. Additionally, grades 1 and 2 der-
matitis occurred in 40% and 51% of patients, respec-
tively [19]. In the current study, grades 1 and 2
dermatitis occurred in 58% and 37% of patients, respec-
tively. Patients had fewer episodes of grade 3 dermatitis
than grades 1 or 2 with POHT. Less severe dermatitis
appeared to occur with POHT. Chen et al. [17] reported
no grade 3 dermatitis in their IMRT experience with
postoperative OCC. Nonetheless, the addition of con-
current chemotherapy to PORT significantly increases
severe adverse effects [4,5]. The proportion of CCRT in
the study by Chen et al.w a s9 % ,b u ti nt h ec u r r e n t
study, it was 84%. A similar reason for lower rate of
mucositis reported by Chen et al.( 1 4 % )[ 1 7 ]a n d
Gomez et al. (23%) [19] could be related to the lower
proportion of patients who received concurrent che-
motherapy. The incidence of body weight loss greater
than 20% of the pre-diagnosis weight among patients
with head and neck cancer undergoing CCRT ranges
from 17%-29% [24,25]. In the current study, no grade 3
body weight loss was noted. (Table 4) Moreover, the
incidence of grade 3 hematologic toxicities for post-
operative OCC patients who received CCRT was 12%-
38% [4,5,14]. In the current study, grade 3 leucopenia
occurred in only 5% of patients, which could have
been related to the different chemotherapy regimens.
Table 4 The selected published series on acute toxicity rate for postoperative external beam radiation therapy/
intensity-modulated radiation therapy/helical tomotherapy for locally advanced head and neck cancer and/or oral
cavity cancer patients
Institute Treatment
(percentage of
using
chemotherapy)
Fistula
formation/or
skin
dehiscence
*≥ Grade 3
dermatitis mucosistis Body
weight
loss
^Xerostomia
(acute)
Anemia Leukopenia Thrombocytopenia
RTOG
9501[4]
OP+RT+C/T - 8% 30% - 2% 38% (all of
hematologic
effects)
EORTC
22931[5]
OP+RT+C/T - - 41% - 14% - 16% -
RTOG
0024[14]
OP+RT+C/T 11% 29% 60% - - 12% (all of
hematologic
effects)
Yu et al.
[23]
OP+RT 8-29% - - - - - - -
Jeremic et
al.[24]
RT+C/T - - - 29% - - - -
Capuano
et al.[25]
RT+C/T - - - 17% - - - -
Gomez et
al.[19]
OP+IMRT +C/T
(29%)
- 3% 23% - 0% - - -
Chen WC
et al.
Taiwan
[17]
OP+IMRT +C/T (9%) - 0 14% - - - - -
FEMH,
Taiwan
OP+HT +C/T (84%) 11% 5% 42% `0% `0% 0% 5% 0%
^Toxicity of xelostomia (Acute): Acute toxicities is defined as occurring < 90 days after beginning RT.
*The grade of toxicity is according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0).
Abbreviations:
OP = operation; RT = External beam radiation therapy; IMRT = intensity-modulated radiation therapy; HT = helical tomotherapy; C/T chemotherapy; FEMH = Far
Eastern Memorial Hospital.
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14% of patients on concurrent PORT and chemotherapy
[4,5]. None of our patients had grade 3 xerostomia.
(Table 4) When the mean parotid radiation dose can be
kept to 26 Gy or less, both objective and subjective
post-treatment improvement in salivary function occurs
[26]. In the current study, the contours of the parotid
g l a n d sw e r en e v e rc h a n g e df r o mt h et r u ev o l u m et o
obtain better dose distributions. Additionally, the opti-
mization parameters could be loosened if concerns were
present regarding adequate tumor coverage. The average
of the median doses for both sides of parotid glands was
25.7 Gy, while the average mean dose for the right side
parotid glands was 29.6 Gy, and that for the left side
parotid glands was 30.1 Gy. In the current study, the
late toxicity for xerostomia was all grade 1, which shows
that POHT has the potential to provide better quality of
life, when given as a definitive treatment for oropharyn-
geal cancer [9].
There are some limitations to our current study. First,
the small case number and the retrospective study
design make drawing statistical conclusions difficult, and
no conclusions about recurrence in comparison with
other modalities can be made. Second, the follow-up
time is short so that late effects are insufficiently
addressed. Third, not all patients who received post-
operative CCRT that caused treatment results belonged
to the pure experience of postoperative high-risk OCC
were treated with POHT with concurrent chemotherapy.
Conclusions
In this retrospective study, high-risk OCC patients
receiving POHT completed the treatment course during
the recommended interval with a high rate of compli-
ance. Treatment toxicity was acceptable even in the set-
ting of concurrent chemotherapy. Long-term follow-up
is needed to confirm these preliminary findings.
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